From soluble Aβ to progressive Aβ aggregation: Could prion-like templated misfolding play a role?

Brain Pathology

Volumn 23, Issue 3, 2013, Pages 333-341

  Eisele, Yvonne S ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

A ; Alzheimer's disease; cerebral amyloidosis; cerebral beta amyloid angiopathy; prion like aggregation; seeding; templated misfolding

Indexed keywords

AMYLOID BETA PROTEIN;

CONFERENCE PAPER; DISEASE COURSE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; NONHUMAN; PRION; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN POLYMERIZATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; HUMANS; PRION DISEASES; PROTEIN STRUCTURE, SECONDARY; PROTEOSTASIS DEFICIENCIES;

EID: 84876208687     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12049     Document Type: Conference Paper

References (95)

1. Aguzzi A, (2009) Cell biology: beyond the prion principle. Nature 459: 924-925.
2. Aguzzi A, Heikenwalder M, Polymenidou M, (2007) Insights into prion strains and neurotoxicity. Nat Rev Mol Cell Biol 8: 552-561.
3. Alzheimer A, (1907) Über eine eigenartige Erkrankung der Hirnrinde. Allg Zeitschr Psychiatr 64: 146-148.
4. Ashe KH, Zahs KR, (2010) Probing the biology of Alzheimer's disease in mice. Neuron 66: 631-645.
5. Askanas V, Engel WK, (2006) Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology 66 (Suppl. 1): S39-S48.
6. Baker HF, Ridley RM, Duchen LW, Crow TJ, Bruton CJ, (1994) Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy. Mol Neurobiol 8: 25-39.
7. Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J, et al (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 96: 732-742.
8. Benzinger TL, Gregory DM, Burkoth TS, Miller-Auer H, Lynn DG, Botto RE, Meredith SC, (1998) Propagating structure of Alzheimer's beta-amyloid(10-35) is parallel beta-sheet with residues in exact register. Proc Natl Acad Sci U S A 95: 13407-13412.
9. Biffi A, Greenberg SM, (2011) Cerebral amyloid angiopathy: a systematic review. J Clin Neurol 7: 1-9.
10. Blennow K, Zetterberg H, Fagan AM, (2012) Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med 2: a006221.
11. Bolmont T, Clavaguera F, Meyer-Luehmann M, Herzig MC, Radde R, Staufenbiel M, et al, (2007) Induction of tau pathology by intracerebral infusion of amyloid-beta-containing brain extract and by amyloid-beta deposition in APPxTau transgenic mice. Am J Pathol 171 (6): 2012-2020.
12. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, et al (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17: 1005-1013.
13. Braak H, Braak E, (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259.
14. Braak H, Braak E, (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18: 351-357.
15. Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, et al (1992) Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem 267: 546-554.
16. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, et al (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3: 67-72.
17. Colby DW, Prusiner SB, (2011) Prions. Cold Spring Harb Perspect Biol 3: a006833.
18. Colletier JP, Laganowsky A, Landau M, Zhao M, Soriaga AB, Goldschmidt L, et al (2011) Molecular basis for amyloid-beta polymorphism. Proc Natl Acad Sci U S A 108: 16938-16943.
19. De Jonghe C, Esselens C, Kumar-Singh S, Craessaerts K, Serneels S, Checler F, et al (2001) Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Gen 10: 1665-1671.
20. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, et al (1996) Increased amyloid-beta42 (43) in brains of mice expressing mutant presenilin 1. Nature 383: 710-713.
21. Duyckaerts C, Delatour B, Potier MC, (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118: 5-36.
22. Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, Yan ZX, et al (2009) Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci U S A 106: 12926-12931.
23. Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, et al (2010) Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330: 980-982.
24. Eisenberg D, Jucker M, (2012) The amyloid state of proteins in human diseases. Cell 148: 1188-1203.
25. Falsig J, Nilsson KP, Knowles TP, Aguzzi A, (2008) Chemical and biophysical insights into the propagation of prion strains. HFSP J 2: 332-341.
26. Fandrich M, (2012) Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity. J Mol Biol 421: 427-440.
27. Gerald Z, Ockert W, (2012) Alzheimer's disease market: hope deferred. Nat Rev Drug Discov 12: 19-20.
28. Ghosh AK, Brindisi M, Tang J, (2012) Developing β-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem 120 (Suppl. 1): 71-83.
29. Gotz J, Chen F, van, Dorpe J, Nitsch RM, (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293: 1491-1495.
30. Goudsmit J, Morrow CH, Asher DM, Yanagihara RT, Masters CL, Gibbs CJ Jr, Gajdusek DC, (1980) Evidence for and against the transmissibility of Alzheimer disease. Neurology 30: 945-950.
31. Graeber MB, Mehraein P, (1999) Reanalysis of the first case of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 249 (Suppl. 3): 10-13.
32. Greenberg SA, (2009) Inclusion body myositis: review of recent literature. Curr Neurol Neurosci Rep 9: 83-89.
33. Haass C, Kaether C, Thinakaran G, Sisodia S, (2012) Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2: a006270.
34. Hamaguchi T, Eisele YS, Varvel NH, Lamb BT, Walker LC, Jucker M, (2012) The presence of Aβ seeds, and not age per se, is critical to the initiation of Aβ deposition in the brain. Acta Neuropathol 123: 31-37.
35. Hardy J, Selkoe DJ, (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
36. Harper JD, Lansbury PT Jr, (1997) Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 66: 385-407.
37. Irwin DJ, Abrams JY, Schonberger LB, Leschek EW, Mills JL, Lee VM, Trojanowski JQ, (2013) Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol 4: 1-7.
38. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van, Eersel J, et al (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142: 387-397.
39. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-128.
40. Jarrett JT, Lansbury PT Jr, (1993) Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73: 1055-1058.
41. Jucker M, (2010) The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med 16: 1210-1214.
42. Jucker M, Walker LC, (2011) Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70: 532-540.
43. Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, et al (2000) Evidence for seeding of beta-amyloid by intracerebral infusion of Alzheimer brain extracts in beta-amyloid precursor protein-transgenic mice. J Neurosci 20: 3606-3611.
44. Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, et al (2001) Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 276: 12991-12998.
45. Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC, Jucker M, (2011) Soluble Aβ seeds are potent inducers of cerebral β-amyloid deposition. J Neurosci 31: 14488-14495.
46. Liu YH, Giunta B, Zhou HD, Tan J, Wang YJ, (2012) Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat Rev Neurol 8: 465-469.
47. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al, (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 15 (3): 853-862.
48. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Dobeli H, et al (2005) 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad Sci U S A 102: 17342-17347.
49. Maarouf CL, Daugs ID, Spina S, Vidal R, Kokjohn TA, Patton RL, et al (2008) Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilin mutations. Mol Neurodegener 3: 20.
50. Mandelkow EM, Mandelkow E, (2012) Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med 2: a006247.
51. Masters CL, Selkoe DJ, (2012) Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med 2: a006262.
52. Mastrangelo P, Mathews PM, Chishti MA, Schmidt SD, Gu Y, Yang J, et al (2005) Dissociated phenotypes in presenilin transgenic mice define functionally distinct gamma-secretases. Proc Natl Acad Sci U S A 102: 8972-8977.
53. Maurer K, Volk S, Gerbaldo H, (1997) Auguste D and Alzheimer's disease. Lancet 349 (9064): 1546-1549.
54. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al, (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46 (6): 860-866.
55. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, et al (2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313: 1781-1784.
56. Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C, (2012) De novo induction of amyloid-β deposition in vivo. Mol Psychiatry 17: 1347-1353.
57. Mucke L, Selkoe DJ, (2012) Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2: a006338.
58. Muller U, Winter P, Graeber MB, (2013) A presenilin 1 mutation in the first case of Alzheimer's disease. Lancet Neurol 12 (2): 129-130.
59. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD, (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283: 1571-1577.
60. Nogalska A, D'Agostino C, Engel WK, Klein WL, Askanas V, (2010) Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol 120: 661-666.
61. Paravastu AK, Qahwash I, Leapman RD, Meredith SC, Tycko R, (2009) Seeded growth of β-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. Proc Natl Acad Sci U S A 106: 7443-7448.
62. Perrin RJ, Fagan AM, Holtzman DM, (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461: 916-922.
63. Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R, (2002) A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci U S A 99: 16742-16747.
64. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, Tycko R, (2005) Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 307: 262-265.
65. Polymenidou M, Cleveland DW, (2012) Prion-like spread of protein aggregates in neurodegeneration. J Exp Med 209: 889-893.
66. Prusiner SB, (1982) Novel proteinaceous infectious particles cause scrapie. Science 216: 136-144.
67. Prusiner SB, (2012) Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336: 1511-1513.
68. Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y, et al (2005) Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurosci 25: 436-445.
69. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, et al (2006) Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7: 940-946.
70. Radde R, Duma C, Goedert M, Jucker M, (2008) The value of incomplete mouse models of Alzheimer's disease. Eur J Nucl Med Mol Imaging 35 (Suppl. 1): S70-S74.
71. Ridley RM, Baker HF, Windle CP, Cummings RM, (2006) Very long term studies of the seeding of beta-amyloidosis in primates. J Neural Transm 113: 1243-1251.
72. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, et al (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316: 750-754.
73. Rosen RF, Fritz JJ, Dooyema J, Cintron AF, Hamaguchi T, Lah JJ, et al (2012) Exogenous seeding of cerebral β-amyloid deposition in βAPP-transgenic rats. J Neurochem 120: 660-666.
74. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB, (2009) Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem 284: 4749-4753.
75. Saido T, Leissring MA, (2012) Proteolytic degradation of amyloid β-protein. Cold Spring Harb Perspect Med 2: a006379.
76. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864-870.
77. Schmidt M, Sachse C, Richter W, Xu C, Fandrich M, Grigorieff N, (2009) Comparison of Alzheimer Abeta(1-40) and Abeta(1-42) amyloid fibrils reveals similar protofilament structures. Proc Natl Acad Sci U S A 106: 19813-19818.
78. Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD, (2009) Neurodegenerative diseases target large-scale human brain networks. Neuron 62: 42-52.
79. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT, (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1: a006189.
80. Stohr J, Watts JC, Mensinger ZL, Oehler A, Grillo SK, DeArmond SJ, et al (2012) Purified and synthetic Alzheimer's amyloid beta (Aβ) prions. Proc Natl Acad Sci U S A 109: 11025-11030.
81. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, et al (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 94: 13287-13292.
82. Tekirian TL, Saido TC, Markesbery WR, Russell MJ, Wekstein DR, Patel E, Geddes JW, (1998) N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits. J Neuropathol Exp Neurol 57: 76-94.
83. Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H, (2006) The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ 2006: re1.
84. Torok M, Milton S, Kayed R, Wu P, McIntire T, Glabe CG, Langen R, (2002) Structural and dynamic features of Alzheimer's Abeta peptide in amyloid fibrils studied by site-directed spin labeling. J Biol Chem 277: 40810-40815.
85. Tycko R, (2011) Solid-state NMR studies of amyloid fibril structure. Ann Rev Phys Chem 62: 279-299.
86. Tycko R, Wickner RB, (2013) Molecular structures of amyloid and prion fibrils: consensus versus controversy. Acc Chem Res. doi: 10.1021/ar300282r.
87. Vattemi G, Nogalska A, King Engel W, D'Agostino C, Checler F, Askanas V, (2009) Amyloid-beta42 is preferentially accumulated in muscle fibers of patients with sporadic inclusion-body myositis. Acta Neuropathol 117: 569-574.
88. Vossel KA, Zhang K, Brodbeck J, Daub AC, Sharma P, Finkbeiner S, et al (2010) Tau reduction prevents Abeta-induced defects in axonal transport. Science 330: 198.
89. Walker LC, Callahan MJ, Bian F, Durham RA, Roher AE, Lipinski WJ, (2002) Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice. Peptides 23: 1241-1247.
90. Walsh DM, Selkoe DJ, (2007) A beta oligomers-a decade of discovery. J Neurochem 101: 1172-1184.
91. Wang J, Dickson DW, Trojanowski JQ, Lee VM, (1999) The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathological aging. Exp Neurol 158 (2): 328-337.
92. Watts JC, Giles K, Grillo SK, Lemus A, DeArmond SJ, Prusiner SB, (2011) Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease. Proc Natl Acad Sci U S A 108: 2528-2533.
93. Wetzel R, (2006) Kinetics and thermodynamics of amyloid fibril assembly. Acc Chem Res 39: 671-679.
94. Wolfe MS, (2007) When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 8: 136-140.
95. Wolfe MS, (2012) γ-Secretase as a target for Alzheimer's disease. Adv Pharmacol 64: 127-153.